Developer docs
API playgroundTry for free, no card

Search company profiles

Prism BioLab

Full company profile

uuid0000uax

Namestring
Prism BioLab
Legal namestring
株式会社PRISM BioLab
Websiteurl
prismbiolab.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

PRISM BioLab is a Japan-based biotechnology company founded in 2006 that develops orally available small-molecule drug candidates against protein-protein interaction (PPI) targets historically classified as "undruggable." The company's core asset is the PepMetics® Technology platform, a proprietary peptidomimetic chemistry system that synthesizes stable, conformationally-locked small molecules mimicking the α-helix and β-turn secondary structures of natural peptides. The platform is supported by three library tiers — a Real Library of 20,000+ synthesized compounds, an On-demand Library capable of producing up to 200,000 molecules from prepared intermediates, and a Virtual Library enabling in silico screening of up to 250 million formulations — together with proprietary analysis tools (PCD Plot, PMA Map), 40+ scaffold types and 50+ side chains, and a patent estate spanning 16 patent families (WO2009/148192 through WO2023/200017).

The company operates a pure B2B business model with no consumer-facing products, generating revenue exclusively through technology licensing, co-development collaborations, and milestone/royalty arrangements with pharmaceutical partners. Its two go-to-market motions are (i) advancing in-house programs to clinical candidates for out-licensing — most notably E7386, a β-catenin/CBP inhibitor co-developed with Eisai and currently in Phase 1 oncology trials — and (ii) "Platform Collaborations," which deploy the PepMetics platform against partner-specified targets. Commercial relationships include major pharma names such as Eisai, Eli Lilly, Ono Pharmaceutical, Ohara Pharmaceutical, Roche/Genentech, Merck KGaA, and Boehringer Ingelheim (the latter agreement having expired in 2025). PRISM completed its IPO on the Tokyo Stock Exchange Growth Market on July 2, 2024 (ticker 206A) and is headquartered in Fujisawa, Kanagawa, with a Tokyo office relocated in January 2026.

Short descriptiontext

PRISM BioLab is a Japan-based biotech (TSE Growth: 206A) that develops orally available small-molecule drug candidates against protein-protein interaction targets using its proprietary PepMetics® peptidomimetic platform, licensing assets and the platform itself to global pharmaceutical partners such as Eisai, Eli Lilly, and Ono Pharmaceutical.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFujisawa, Japan
HQ citystring
Fujisawa
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide mimetic drug discovery, protein-protein interaction inhibitors, intrinsically disordered proteins, structure-based drug design, small molecule peptidomimetics
Industry1 code
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Peptide Mimetic Drug Discovery Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Revenue
TypeLicensing Royalties
Description

PRISM licenses its technology and compounds to pharmaceutical partners. Revenue includes upfront payments, milestone payments upon achievement of research and development milestones, and potential royalties on future sales.

ir.prismbiolab.com
2Milestone Payments
TypeLicensing Royalties
Description

The company receives milestone payments as collaborative research progresses through various stages. For example, achieved initial milestone and received payment from Ono Pharmaceutical in November 2025 for oncology drug discovery collaboration.

prnewswire.com
3Series C Funding
TypeLicensing Royalties
Description

Raised ¥1.3 billion (approximately $9.3 million) in Series C funding on August 27, 2021, from investors including santec Holdings.

prismbiolab.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PRISM BioLab is a biotechnology company that develops PepMetics® Technology, a proprietary drug discovery platform for creating peptide mimetic small molecules that mimic α-helix or β-turn peptides using unique, stable scaffolds. The company maintains a PepMetics® Real Library of more than 20,000 compounds and offers on-demand synthesis services, enabling partners to drug historically challenging protein-protein interaction targets and intrinsically disordered proteins.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • E7386 Phase 1 clinical trial completed with results published in ESMO OPEN; cardiac safety data shared at ASCO Annual Meeting 2025
+2 more records
Product overview1 text field

PRISM BioLab is a biotechnology company with a unified PepMetics® Technology platform centered on proprietary peptide mimetic small molecules that mimic α-helix and β-turn peptides. The platform comprises the core PepMetics® Technology (for synthesizing molecules that act like peptides but can be synthesized like small molecules), supported by three library tiers (Real Library with 20,000+ synthesized compounds, On-demand Library for rapid synthesis of up to 200K compounds, and Virtual Library for screening 250M+ formulations). Supporting technology modules include Sequence Mimetics, Structure-Based Drug Design, and IDP targeting. The company operates two business models: In-house Pipelines advancing programs to clinical candidates for licensing, and Platform Collaborations providing the platform to pharmaceutical partners. Key clinical candidates include E7386 (jointly developed with Eisai, Phase 1 for oncology) and FEP600/FEP633 (eIF4E/eIF4G1 inhibitors in lead optimization).

Product and service1 record
1PepMetics Technology
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-13
Description

Drug discovery collaboration to develop an integrated AI-navigated, physics-guided platform for discovering orally available small molecules targeting protein-protein interactions, membrane proteins, and complex receptor systems. Combines PRISM's PepMetics chemistry with Receptor.AI's multi-objective AI navigation engine. Initial focus on metabolic diseases including obesity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

Collaboration to develop inhibitors targeting transcription factors (TF) and protein-protein interactions (PPI). Uses Talus Bio's assay technologies with PRISM's chemistry and small-molecule libraries to discover and optimize new drug candidates for challenging targets.

3Ono Pharmaceutical Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-14
Description

Drug discovery collaboration focused on oncology. Involves development of small molecule inhibitors targeting protein-protein interactions. Initial research milestone achieved with milestone payment received in November 2025.

en.prnasia.com
4Eisai Co., Ltd.
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-05-25
Description

Co-development of E7386, a selective inhibitor of β-catenin/CBP interaction. Phase 1 clinical trial completed with results published in ESMO OPEN. Cardiac safety evaluation results shared at ASCO Annual Meeting 2025. Preclinical research results presented at AACR Annual Meeting 2026.

prismbiolab.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-29
Description

License and research collaboration on a protein-protein interaction target. PRISM granted rights to Lilly for use of its technology on specific targets.

6Ohara Pharmaceutical Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-05-01
Description

License agreement for PRI-724 compound. Clinical milestone achieved in May 2023 as Ohara advanced OP-724 clinical trials. This represents a significant validation of PRISM's technology.

prismbiolab.com
7Boehringer Ingelheim International GmbH
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research and license agreement for novel targets. The agreement has expired as announced in 2025.

prismbiolab.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as partner on company partners page. Nature of collaboration not specified in detail in available sources.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as partner on company partners page. Nature of collaboration not specified in detail in available sources.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1PeptiDream
TypeDirect peer
Description

Japanese peptide-based drug discovery platform company using non-standard peptide libraries to address challenging targets including PPIs. Direct comparison to PRISM given shared Japan base, peptide-focused platform approach, and pharma partnership model.

TypeDirect peer
Description

Clinical-stage biotech developing bicyclic peptide therapeutics (bicycles) that combine attributes of small molecules and biologics to drug PPIs and oncology targets. Direct peer to PRISM in peptide-inspired therapeutic discovery targeting PPIs.

TypeDirect peer
Description

Pioneer in targeted protein degradation (PROTACs) for PPIs and previously 'undruggable' targets, with pharma partnerships and clinical-stage oncology pipeline. Direct peer to PRISM in addressing PPIs with novel small-molecule modalities.

TypeDirect peer
Description

Clinical-stage biotech developing small-molecule protein degraders (Pegasus platform) targeting PPIs in immunology and oncology. Direct peer in the small-molecule PPI targeting space with major pharma partnerships.

5Morphic Therapeutic
TypeDirect peer
Description

Clinical-stage biotech developing oral small-molecule inhibitors of integrins and other PPIs using structure-based design. Direct peer to PRISM in structure-based small-molecule design against high-value PPIs.

TypeDirect peer
Description

Clinical-stage biotech targeting chromatin regulatory complexes and PPIs in oncology. Comparable to PRISM in using novel chemistry platforms to drug challenging protein-protein interactions and transcription factor targets.

TypeDirect peer
Description

Biotech developing allosteric small molecules targeting PPIs and protein functions through natural regulatory hotspots. Direct peer in targeting previously 'undruggable' PPIs with proprietary small-molecule chemistry.

8Aileron Therapeutics
TypeDirect peer
Description

Developer of stapled peptide therapeutics designed to stabilize alpha-helical structures and disrupt PPIs. Closely comparable technology approach to PRISM's peptide-mimetic scaffold strategy for PPI modulation.

TypeDirect peer
Description

Clinical-stage degrader company developing small-molecule degraders (dTAGs) targeting disease-causing proteins. Direct peer in targeting PPIs and protein functions with novel small-molecule platforms and pharma partnerships.

10Eisai Co., Ltd.
TypeBroad incumbent
Description

Major Japanese pharmaceutical company and PRISM's flagship partner for E7386 co-development. Broad incumbent that also operates its own internal PPI/small-molecule programs and competes for partnerships in oncology and neuroscience.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prism BioLab

Peptide Mimetic Drug Discovery Platformprismbiolab.com

PRISM BioLab is a Japan-based biotech (TSE Growth: 206A) that develops orally available small-molecule drug candidates against protein-protein interaction targets using its proprietary PepMetics® peptidomimetic platform, licensing assets and the platform itself to global pharmaceutical partners such as Eisai, Eli Lilly, and Ono Pharmaceutical.

What Prism BioLab does

PRISM BioLab is a Japan-based biotechnology company founded in 2006 that develops orally available small-molecule drug candidates against protein-protein interaction (PPI) targets historically classified as "undruggable." The company's core asset is the PepMetics® Technology platform, a proprietary peptidomimetic chemistry system that synthesizes stable, conformationally-locked small molecules mimicking the α-helix and β-turn secondary structures of natural peptides. The platform is supported by three library tiers — a Real Library of 20,000+ synthesized compounds, an On-demand Library capable of producing up to 200,000 molecules from prepared intermediates, and a Virtual Library enabling in silico screening of up to 250 million formulations — together with proprietary analysis tools (PCD Plot, PMA Map), 40+ scaffold types and 50+ side chains, and a patent estate spanning 16 patent families (WO2009/148192 through WO2023/200017).

The company operates a pure B2B business model with no consumer-facing products, generating revenue exclusively through technology licensing, co-development collaborations, and milestone/royalty arrangements with pharmaceutical partners. Its two go-to-market motions are (i) advancing in-house programs to clinical candidates for out-licensing — most notably E7386, a β-catenin/CBP inhibitor co-developed with Eisai and currently in Phase 1 oncology trials — and (ii) "Platform Collaborations," which deploy the PepMetics platform against partner-specified targets. Commercial relationships include major pharma names such as Eisai, Eli Lilly, Ono Pharmaceutical, Ohara Pharmaceutical, Roche/Genentech, Merck KGaA, and Boehringer Ingelheim (the latter agreement having expired in 2025). PRISM completed its IPO on the Tokyo Stock Exchange Growth Market on July 2, 2024 (ticker 206A) and is headquartered in Fujisawa, Kanagawa, with a Tokyo office relocated in January 2026.

Prism BioLab firmographics

Firmographics
Name
Prism BioLab
Legal name
株式会社PRISM BioLab
Website
https://prismbiolab.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
PRISM BioLab is a Japan-based biotech (TSE Growth: 206A) that develops orally available small-molecule drug candidates against protein-protein interaction targets using its proprietary PepMetics® peptidomimetic platform, licensing assets and the platform itself to global pharmaceutical partners such as Eisai, Eli Lilly, and Ono Pharmaceutical.
Ownership category
akta.pro rank

Prism BioLab industry classification

Industry
Product category
Peptide Mimetic Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Peptide mimetic drug discovery
  • Protein-protein interaction inhibitors
  • Intrinsically disordered proteins
  • Structure-based drug design
  • Small molecule peptidomimetics

Where Prism BioLab is headquartered

Location

Headquarters

HQ city
Fujisawa
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

Prism BioLab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Others

Revenue model

  1. Licensing Revenue: PRISM licenses its technology and compounds to pharmaceutical partners. Revenue includes upfront payments, milestone payments upon achievement of research and development milestones, and potential royalties on future sales.
  2. Milestone Payments: The company receives milestone payments as collaborative research progresses through various stages. For example, achieved initial milestone and received payment from Ono Pharmaceutical in November 2025 for oncology drug discovery collaboration.
  3. Series C Funding: Raised ¥1.3 billion (approximately $9.3 million) in Series C funding on August 27, 2021, from investors including santec Holdings.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Prism BioLab product offering

Product offering

Core offering

PRISM BioLab is a biotechnology company that develops PepMetics® Technology, a proprietary drug discovery platform for creating peptide mimetic small molecules that mimic α-helix or β-turn peptides using unique, stable scaffolds. The company maintains a PepMetics® Real Library of more than 20,000 compounds and offers on-demand synthesis services, enabling partners to drug historically challenging protein-protein interaction targets and intrinsically disordered proteins.

Product overview

PRISM BioLab is a biotechnology company with a unified PepMetics® Technology platform centered on proprietary peptide mimetic small molecules that mimic α-helix and β-turn peptides. The platform comprises the core PepMetics® Technology (for synthesizing molecules that act like peptides but can be synthesized like small molecules), supported by three library tiers (Real Library with 20,000+ synthesized compounds, On-demand Library for rapid synthesis of up to 200K compounds, and Virtual Library for screening 250M+ formulations). Supporting technology modules include Sequence Mimetics, Structure-Based Drug Design, and IDP targeting. The company operates two business models: In-house Pipelines advancing programs to clinical candidates for licensing, and Platform Collaborations providing the platform to pharmaceutical partners. Key clinical candidates include E7386 (jointly developed with Eisai, Phase 1 for oncology) and FEP600/FEP633 (eIF4E/eIF4G1 inhibitors in lead optimization).

Differentiator

Problem solved

Functional benefit

Products and services

  • PepMetics Technology

Quantifiable outcome

  • E7386 Phase 1 clinical trial completed with results published in ESMO OPEN; cardiac safety data shared at ASCO Annual Meeting 2025
  • +2 more outcomes

Companies that use Prism BioLab

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Prism BioLab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Prism BioLab partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

  • Receptor.AI Inc.coreTechnology or Integration · 13 March 2026Drug discovery collaboration to develop an integrated AI-navigated, physics-guided platform for discovering orally available small molecules targeting protein-protein interactions, membrane proteins, and complex receptor systems. Combines PRISM's PepMetics chemistry with Receptor.AI's multi-objective AI navigation engine. Initial focus on metabolic diseases including obesity.
  • Talus BiosciencecoreStrategic or Co-development Partner · 17 December 2025Collaboration to develop inhibitors targeting transcription factors (TF) and protein-protein interactions (PPI). Uses Talus Bio's assay technologies with PRISM's chemistry and small-molecule libraries to discover and optimize new drug candidates for challenging targets.
  • Ono Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 14 November 2025Drug discovery collaboration focused on oncology. Involves development of small molecule inhibitors targeting protein-protein interactions. Initial research milestone achieved with milestone payment received in November 2025.
  • Eisai Co., Ltd.flagshipStrategic or Co-development Partner · 25 May 2025Co-development of E7386, a selective inhibitor of β-catenin/CBP interaction. Phase 1 clinical trial completed with results published in ESMO OPEN. Cardiac safety evaluation results shared at ASCO Annual Meeting 2025. Preclinical research results presented at AACR Annual Meeting 2026.
  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 29 November 2023License and research collaboration on a protein-protein interaction target. PRISM granted rights to Lilly for use of its technology on specific targets.
  • Ohara Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 1 May 2018License agreement for PRI-724 compound. Clinical milestone achieved in May 2023 as Ohara advanced OP-724 clinical trials. This represents a significant validation of PRISM's technology.
  • Boehringer Ingelheim International GmbHminorStrategic or Co-development PartnerResearch and license agreement for novel targets. The agreement has expired as announced in 2025.
  • Roche / GenentechminorStrategic or Co-development PartnerListed as partner on company partners page. Nature of collaboration not specified in detail in available sources.
  • Merck KGaAminorStrategic or Co-development PartnerListed as partner on company partners page. Nature of collaboration not specified in detail in available sources.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Prism BioLab competitors and assessment

Company assessment

Direct peers

  • PeptiDream: Japanese peptide-based drug discovery platform company using non-standard peptide libraries to address challenging targets including PPIs. Direct comparison to PRISM given shared Japan base, peptide-focused platform approach, and pharma partnership model.
  • Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide therapeutics (bicycles) that combine attributes of small molecules and biologics to drug PPIs and oncology targets. Direct peer to PRISM in peptide-inspired therapeutic discovery targeting PPIs.
  • Arvinas: Pioneer in targeted protein degradation (PROTACs) for PPIs and previously 'undruggable' targets, with pharma partnerships and clinical-stage oncology pipeline. Direct peer to PRISM in addressing PPIs with novel small-molecule modalities.
  • Kymera Therapeutics: Clinical-stage biotech developing small-molecule protein degraders (Pegasus platform) targeting PPIs in immunology and oncology. Direct peer in the small-molecule PPI targeting space with major pharma partnerships.
  • Morphic Therapeutic: Clinical-stage biotech developing oral small-molecule inhibitors of integrins and other PPIs using structure-based design. Direct peer to PRISM in structure-based small-molecule design against high-value PPIs.
  • Foghorn Therapeutics: Clinical-stage biotech targeting chromatin regulatory complexes and PPIs in oncology. Comparable to PRISM in using novel chemistry platforms to drug challenging protein-protein interactions and transcription factor targets.
  • HotSpot Therapeutics: Biotech developing allosteric small molecules targeting PPIs and protein functions through natural regulatory hotspots. Direct peer in targeting previously 'undruggable' PPIs with proprietary small-molecule chemistry.
  • Aileron Therapeutics: Developer of stapled peptide therapeutics designed to stabilize alpha-helical structures and disrupt PPIs. Closely comparable technology approach to PRISM's peptide-mimetic scaffold strategy for PPI modulation.
  • C4 Therapeutics: Clinical-stage degrader company developing small-molecule degraders (dTAGs) targeting disease-causing proteins. Direct peer in targeting PPIs and protein functions with novel small-molecule platforms and pharma partnerships.

Broad incumbents

  • Eisai Co., Ltd. Major Japanese pharmaceutical company and PRISM's flagship partner for E7386 co-development. Broad incumbent that also operates its own internal PPI/small-molecule programs and competes for partnerships in oncology and neuroscience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Prism BioLab social profiles

Digital presence

Prism BioLab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prism BioLab leadership team

Management profile

Number of profiles

Profiles1 record

Prism BioLab funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prism BioLab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prism BioLab

What does Prism BioLab do?

PRISM BioLab is a biotechnology company that develops PepMetics® Technology, a proprietary drug discovery platform for creating peptide mimetic small molecules that mimic α-helix or β-turn peptides using unique, stable scaffolds. The company maintains a PepMetics® Real Library of more than 20,000 compounds and offers on-demand synthesis services, enabling partners to drug historically challenging protein-protein interaction targets and intrinsically disordered proteins.

Is Prism BioLab a public or private company?

Prism BioLab is a public company. It is classified as unknown and is currently operating.

When was Prism BioLab founded?

Prism BioLab was founded in 2006. It employs 11 to 50 people.

Where is Prism BioLab based?

Prism BioLab is headquartered in Fujisawa, Japan, in the Asia region.

How does Prism BioLab make money?

Three revenue lines are on record. Licensing Revenue is the primary driver. The others are milestone Payments and series C Funding.

Who are Prism BioLab's main competitors?

Direct peers on record are PeptiDream, Bicycle Therapeutics, Arvinas, Kymera Therapeutics, Morphic Therapeutic, Foghorn Therapeutics, HotSpot Therapeutics, Aileron Therapeutics and C4 Therapeutics. Eisai Co., Ltd. is listed as a broad incumbent.

Does Prism BioLab have an API?

No public API is recorded for Prism BioLab.

What industry is Prism BioLab in?

Prism BioLab's product category is Peptide Mimetic Drug Discovery Platform. Its primary akta.pro industry code is HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StWe Think PRISM BioLabLTD (TSE:206A) Can Afford To Drive Business GrowthThis article by Simply Wall St analyzes the cash burn and financial health of PRISM BioLabLTD (TSE:206A), a Japanese biotech company. As of March 2026, the company held JP¥2.5 billion in cash with no debt, burning through JP¥1.3 billion annually for a runway of approximately 22 months. While cash burn increased 19% year-on-year, revenue grew 74%, and the author concludes the company's growth trajectory is relatively promising despite the inherent risks of cash-burning companies.The Pharma LetterPRISM BioLab and Receptor.AI collaborate on molecule discoveryPRISM BioLab and Receptor.AI signed a drug discovery collaboration to develop an AI-navigated, physics-guided platform for small molecules targeting intracellular PPIs, membrane proteins, and complex receptors. The partnership combines PRISM's PepMetics chemistry with Receptor.AI's AI engine, focusing on metabolic diseases like obesity.MorningstarPRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration AgreementPRISM BioLab and Receptor.AI have entered into a drug discovery collaboration agreement to develop an integrated, AI-navigated, physics-guided platform for discovering orally available small molecules targeting protein-protein interactions, membrane proteins, and complex receptor systems. The collaboration combines PRISM's PepMetics chemistry with Receptor.AI's multi-objective AI navigation engine, initially focusing on metabolic diseases including obesity. The companies aim not only to generate clinical candidates but also to jointly engage pharmaceutical partners and showcase their combined technologies as a basis for future collaborative opportunities.PrtimesPRISM BioLabとReceptor.AI、創薬提携契約締結のお知らせPRISM BioLab Co., Ltd. and Receptor.AI Inc. have announced a drug discovery partnership to develop small molecule drugs targeting protein-protein interactions (PPI) and membrane proteins, combining PRISM's PepMetics® technology with Receptor.AI's AI-powered molecular design platform. The collaboration will initially focus on metabolic diseases, aiming to generate innovative hit compounds, lead compounds, and clinical candidate compounds through the integration of both companies' proprietary technologies. Both companies share a philosophy of "challenging drug discovery with new approaches" and intend to build a data-driven optimized drug discovery cycle while seeking collaborative research opportunities with pharmaceutical companies.PR NewswirePRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration AgreementPRISM BioLab Co., Ltd. and Receptor.AI Inc. announced they have entered into a drug discovery collaboration agreement to develop an integrated AI-navigated platform for discovering orally available small molecules targeting protein-protein interactions and membrane proteins. The collaboration combines PRISM's PepMetics® chemistry technology with Receptor.AI's physics-informed molecular design capabilities, initially focusing on a selected receptor target for metabolic disease including obesity. The companies also intend to jointly engage pharmaceutical partners and use the collaboration to showcase their combined technologies as a basis for acquiring know-how and expanding future collaborative opportunities.PR NewswirePRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction TargetsPRISM BioLab and Talus Bioscience announced a collaboration to discover novel inhibitors of transcription factor and protein-protein interaction targets. The partnership combines PRISM's PepMetics® chemistry with Talus Bio's AI-guided regulome profiling screens to identify compounds against challenging therapeutic targets. Both companies will share the costs of discovery research and any profits generated from commercialization.PR Newswire APACPRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction TargetsPRISM BioLab and Talus Bioscience have entered into a collaboration to discover novel inhibitors of transcription factor and protein-protein interaction targets, combining Talus Bio's assay technologies and AI-guided regulome profiling with PRISM's small-molecule libraries. The companies will share research costs and any profits from out-licensing or commercialization of discovered drug products. The collaboration aims to develop first-in-class compounds with direct functional effects on TF and PPI activity in live human cells, targeting historically 'undruggable' proteins.PR Newswire APACPRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.PRISM BioLab and Ono Pharmaceutical have achieved the initial milestone in their drug discovery collaboration targeting oncology, with PRISM confirming receipt of a milestone payment. The milestone was defined under a Joint Research and Licensing Agreement signed on April 25, 2024, for discovering clinical candidate compounds using PRISM's proprietary PepMetics technology. The milestone payment will be recorded as revenue in PRISM's fiscal year ending September 2026, with additional milestone payments and potential commercialization royalties to follow as the research progresses.MorningstarPRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction TargetsPRISM BioLab and Elix announced a drug discovery collaboration effective April 1, 2025, to combine PepMetics peptide-mimetic technology with Elix's AI platform. The partnership aims to accelerate identification of compounds for protein-protein interaction targets, reducing time and costs. It expects to improve success rates and deliver treatments for unmet medical needs.YahooPRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction TargetsPRISM BioLab and Elix announced a drug discovery collaboration effective April 1, 2025, combining PepMetics peptide-mimetic technology with Elix's AI platform. The partnership aims to accelerate identification of compounds for protein-protein interaction targets, building on a successful pilot project.